MedTrace Logo

Value of Von Willebrand Factor in Portal Hypertension

NCT01358123 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2015-09-25

No results posted yet for this study

Summary

In patients with liver cirrhosis elevated levels of von Willebrand factor antigen (vWF-Ag) are found frequently but the clinical significance is unclear. vWF-Ag plays an important role in primary haemostasis and development of thrombotic vascular obliteration is discussed as a possible mechanism leading to portal hypertension. Invasive measurement of hepatic venous pressure gradient (HVPG) is the current gold standard for the diagnosis of portal hypertension. The investigators hypothesize that vWF-Ag levels in plasma may correlate with portal pressure and predict clinically significant portal hypertension (CSPH, HVPG \>=10mmHg) and its complications.

Conditions

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Arnulf Ferlitsch, MD · Medical University of Vienna

Eligibility

Min Age
18 Years
Max Age
98 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2016-05-31
Completion
2016-06-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01358123 on ClinicalTrials.gov